Clinical effects of erdosteine in the treatment of acute respiratory tract diseases in children

Balli, Fiorella; Bergamini, Barbara Maria; Calistru, Petre Iacob; Ciofu, Ep; R, Domenici; Doros, Gheorghe; Dragomir, Dimitrie; Gherghina, I; Iordăchescu, F; Murgoci, G; Orăşanu, D; Pleșca, Doina Anca; Vaccaro, Alessandra; Assereto, R.

doi:10.5414/cpp45016

Cited by 28 publications

(18 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We suggest that these clinical results are associated with the antibacterial, antioxidant, and mucolytic effects of erdosteine [35, 36]. The positive effect of erdosteine in PCOS is likely to be associated with the thiol groups in its structure.…”

Section: Discussionmentioning

confidence: 99%

Investigation of Therapeutic Effects of Erdosteine on Polycystic Ovary Syndrome in a Rat Model

Karateke¹,

Dokuyucu²,

Doğan

et al. 2018

Med Princ Pract

View full text Add to dashboard Cite

Objective: Polycystic ovary syndrome (PCOS) is a serious endocrine disorder. In the present study, we investigated the therapeutic effects of erdosteine in letrozole-induced PCOS in rats. Methods: Thirty-two Wistar albino female rats were grouped as control group (C), PCOS group (PCOS), PCOS-metformin group (PCOS+MET), and PCOS-erdosteine group (PCOS+Erd). PCOS was induced by administering letrozole; such rats presented with sex hormone disorder, abnormal estrous cycles determined by daily vaginal smear, large cystic follicles, and increasing fasting insulin levels. After induction of PCOS, metformin (500 mg/kg/day) and erdosteine (100 mg/kg/day) were given orally to the treatment groups for 30 days. Serum concentrations of glucose, total cholesterol, low- and high-density lipoprotein, triglyceride, as well as the total oxidant and antioxidant status, oxidative stress index, circulating estrone (E1), estradiol (E2), testosterone, and androstenedione were evaluated. The ovaries were graded histologically. Results: Weights of ovarian tissues (p < 0.05) and the number of atretic follicles (p < 0.001) and cystic follicles (p < 0.01) decreased in the PCOS+Erd group; the corpus luteum number was significantly higher in the PCOS+Erd group (p < 0.01) as compared with the PCOS group. Lipid parameters (total-C, LDL-C, and TG), E1 (estrone), E1/E2 ratio, testosterone, and androstenedione significantly decreased, while HDL-C and E2 (estradiol) significantly increased in the PCOS+Erd group as compared with the PCOS group. Moreover glucose, insulin, and HOMA-IR were reduced with treatment of erdosteine (p > 0.05, p < 0.001, and p < 0.001, respectively). Conclusion: It is suggested that erdosteine may be used in the treatment of PCOS as an alternative to metformin. It appears that our findings might be supported by clinical and molecular studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Investigation of Therapeutic Effects of Erdosteine on Polycystic Ovary Syndrome in a Rat Model

Karateke¹,

Dokuyucu²,

Doğan

et al. 2018

Med Princ Pract

View full text Add to dashboard Cite

show abstract

“…We attempted to contact the trial authors but were not able to extract data on the subgroup of patients with pneumonia, and thus we excluded the trial from further analysis. In the 2009 update (Chang 2010), we identified two studies on erdosteine (a mucolytic agent) but these were excluded as they are available only on medical prescription in countries with tight regulatory control of medications such as USA, Australia and the UK (Balli 2007;Titti 2000). In this 2011 update, we identified 32 potential studies but none fulfilled the inclusion criteria.…”

Section: Results Of the Searchmentioning

confidence: 99%

Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults

Chang

Cheng

Chang

2012

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Cough is often distressing for patients with pneumonia. Accordingly they often use over-the-counter (OTC) cough medications (mucolytics or cough suppressants). These might provide relief in reducing cough severity, but suppression of the cough mechanism might impede airway clearance and cause harm. Objectives To evaluate the efficacy of OTC cough medications as an adjunct to antibiotics in children and adults with pneumonia.

show abstract

“…Перспективным (сходным с ацетилцистеином) препаратом, оказывающим прямое мукоактивное дей-ствие, является эрдостеин, эффективность которого обусловлена тиоловыми группами его активных мета-болитов [25]. Однако пока препарат применяется толь-ко у взрослых пациентов с хронической обструктивной болезнью легких и детям до 18 лет противопоказан.…”

Section: обзоры литературыunclassified

Differentiation mucolytic therapy for acute and chronic bronchopulmonary diseases in pediatric practice

Мизерницкий¹,

Мельникова²

2016

Ross. vestn. perinatol. pediatr.

View full text Add to dashboard Cite

Clinical effects of erdosteine in the treatment of acute respiratory tract diseases in children

Cited by 28 publications

References 17 publications

Investigation of Therapeutic Effects of Erdosteine on Polycystic Ovary Syndrome in a Rat Model

Investigation of Therapeutic Effects of Erdosteine on Polycystic Ovary Syndrome in a Rat Model

Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults

Differentiation mucolytic therapy for acute and chronic bronchopulmonary diseases in pediatric practice

Contact Info

Product

Resources

About